Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

03/20/2018) Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual

systemic therapy
autoimmune disease
brain metastases
carcinoid
giant cell tumors
  • 6048 views
  • 22 Sep, 2021
  • 818 locations
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used …

  • 0 views
  • 30 Jan, 2021
  • 1 location
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue. Furthermore, there is growing evidence demonstrating both safety and efficacy for SBRT. We propose that these advantages are translatable to the adjuvant treatment of endometrial cancer. We submit …

carcinoma
systemic therapy
immunomodulators
cancer chemotherapy
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage

Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease. Most cases of high grade ovarian cancer develop in the fallopian tubes, hence the universal recommendation for high-risk populations (e.g., BRCA1/2 mutation carriers) is to undergo risk-reducing bilateral …

BRCA2
cavity
cancer of the ovary
carcinoma
ovarian carcinoma
  • 4 views
  • 24 Jan, 2021
  • 5 locations
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

This is an open-label, single arm, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab in monotherapy in metastatic patients with Programmed Death-1 (PD1)-high-expressing tumors.

cancer
measurable disease
alopecia
  • 0 views
  • 22 Aug, 2021
  • 10 locations